Targeted Cancer Therapy: Tyrosine Kinase Inhibitors
Abstract
Cancers generally contain multiple genetic and epigenetic abnormalities, but several key genes maintain the malignant phenotype and cellular survival. Tyrosine kinases are often involved in the cellular response with growth factors, cytokines, and hormones. These molecules are responsible for tumor growth by various mechanisms. It is thought that tyrosine kinase inhibitors may have a wide range of therapeutic efficacy. Significant response rates could not be obtained in phase 1 studies with any of the agents in monotherapy, and other options are being investigated by administering high doses in short periods and combining drugs that may affect different pathways.
Keywords
Kaynakça
- 1. Maruyama IN. Mechanisms of activation of receptor tyrosine kinases: Monomers or dimers. Cell. 2014;3:304-330.
- 2. Posner I, Engel M, Gazit A, Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Molecular Pharmacology. 1994;45:673-683.
- 3.FDA Approved Drugs for Oncology. 2018. Available from: www.centerwatch.com/druginformation/fda-approved-drugs/therapeutic-area/12/oncology.
- 4. Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. The Oncologist. 2007;12:325-330.
- 5. Sillaber C, Mayerhofer M, Agis H, Sagaster V, Mannhalter C, Sperr WR et al. Chronic myeloid leukemia: Pathophysiology, diagnostic parameters, and current treatment concepts. Wiener Klinische Wochenschrift. 2003;115:485-504.
- 6. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. The New England Journal of Medicine. 2003;349:1423-1432.
- 7. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114:1126.
- 8. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology. 2003;21:4342-4349.
- 9. Kerob D, Porcher R, Vérola O, Dalle S, Maubec E, Aubin F et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: Results of a multicenter phase II study on 25 patients. Clinical Cancer Research. 2010;16:3288-3295.
- 10. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20:975-980.
